Faruqi and Faruqui, LLP Logo
Share this page

IntelliPharmaCeutics International Inc. (IPCI)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In IntelliPharmaCeutics International Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at IntelliPharmaCeutics International Inc. (“IntelliPharmaCeutics” or the “Company”) (NasdaqCM:IPCI).

The investigation focuses on whether the Company and its executives violated federal securities laws.  Specifically, on July 24, 2017, U.S. Food and Drug Administration (“FDA”) scientists expressed concerns that the Company failed to provide sufficient data regarding the abuse potential of its opioid painkilling drug, Rexista.  Then, on July 26, 2017, the Company announced that two advisory committees of the FDA voted 22 to 1 to oppose the Company’s New Drug Application for Rexista, citing insufficient data regarding the drug’s abuse-deterrent properties as a motivating concern.

Following these announcements, IntelliPharmaCeutics’s share price declined significantly, causing harm to investors.

If you invested in IntelliPharmaCeutics stock or options and would like to discuss your legal rights, please fill out the form below.  There is no cost or obligation to you.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    IntelliPharmaCeutics International Inc. (IPCI)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 07/27/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.